Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is noninferior to continuing current antiretroviral therapy.

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Rectal cancer is occurring earlier and killing younger adults faster, according to a study presented at Digestive Disease Week 2026, held from May 2 to 5 in Chi ...

HealthDay News — For adults with prediabetes, a reduction in the risk for diabetes is seen after supplementation with 4000 IU/day of vitamin D 3 among those carrying the AC and CC alleles of the Apal ...

MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.

Difference in total body weight loss between the treatment and control groups widened with time postintervention.

The SYNCHRONIZE-1 trial evaluated survodutide in non-diabetic adults with obesity or overweight with at least 1 weight-related complication.

Breztri Aerosphere is a single-inhaler fixed-dose triple therapy that combines budesonide, glycopyrrolate, and formoterol fumarate.

Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.

Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive fungal diseases in HSCT patients.

Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.

Improvements in some domains of cognitive function seen for patients with cancer receiving chemotherapy reporting cognitive problems.